Maxime Dely – The French Transfusion landscape is Evolving
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The French transfusion landscape is evolving
As hospital needs change and health sovereignty becomes a national priority, the 2024 Annual Report of the French Blood Establishment (EFS) highlights a major transformation in the countryโs transfusion system.
Red blood cell use continues to decline
The number of red blood cell (RBC) units issued keeps decreasing:
- 2,081,938 units delivered in 2024
- -3.4 % compared to 2023
This trend reflects:
โข More efficient use of transfusion indications
โข Improved patient blood management
โข Optimization of clinical practices
Plasma takes center stage
Conversely, plasma collection is growing rapidly:
- 867,127 liters of plasma for fractionation delivered in 2024 (+4.8%)
- +1.4 % plasma donors in one year
This growth supports the national strategy โAmbition Plasmaโ, with an ambitious goal:
1.4 million liters of plasma collected per year by 2028
To reach this target, EFS is:
โข Progressively shifting from whole blood to plasma donations,
โข Opening new donation centers and time slots,
โข Expanding remote medical supervision (tele-assistance) to facilitate apheresis donations.
A strong and encouraging donor engagement
In 2024:
- 1,506,534 donors – including 17 % new donors
- 29 % under 30 years old – a promising new generation of donors
- A strong sense of commitment that secures the future of blood and plasma supply
The generational renewal is a key success factor for sustaining the transfusion system in the years to come.
A structural shift
2024 confirms a deep transformation:
- Fewer red blood cell transfusions
- More plasma collected, better utilized, and more strategic than ever
A crucial evolution to meet therapeutic needs, strengthen the national supply of plasma-derived medicines, and support France’s health sovereignty.
What’s next?
How can we accelerate this transition while maintaining donor loyalty and the right balance between all blood components?
Iโd love to hear your insights, experiences, and perspectives.”

Stay updated with Hemostasis Today.
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies